223 related articles for article (PubMed ID: 36975507)
1. Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant-Novel Insights from Computer-Aided Drug Discovery.
Ramalingam PS; Balakrishnan P; Rajendran S; Jothi A; Ramalingam R; Arumugam S
Curr Issues Mol Biol; 2023 Mar; 45(3):2136-2156. PubMed ID: 36975507
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS
Issahaku AR; Mukelabai N; Agoni C; Rudrapal M; Aldosari SM; Almalki SG; Khan J
Sci Rep; 2022 Oct; 12(1):17796. PubMed ID: 36273239
[TBL] [Abstract][Full Text] [Related]
3. Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods.
Kulkarni AM; Kumar V; Parate S; Lee G; Yoon S; Lee KW
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163234
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations.
Du Z; Tu G; Gong Y; Fu X; Wu Q; Long G
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542866
[TBL] [Abstract][Full Text] [Related]
5. In Silico Prediction of New Inhibitors for Kirsten Rat Sarcoma G12D Cancer Drug Target Using Machine Learning-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulation Approaches.
Ajmal A; Danial M; Zulfat M; Numan M; Zakir S; Hayat C; Alabbosh KF; Zaki MEA; Ali A; Wei D
Pharmaceuticals (Basel); 2024 Apr; 17(5):. PubMed ID: 38794122
[TBL] [Abstract][Full Text] [Related]
6. Flavonoids as potential KRAS inhibitors: DFT, molecular docking, molecular dynamics simulation and ADMET analyses.
Prinsa ; Saha S; Bulbul MZH; Ozeki Y; Alamri MA; Kawsar SMA
J Asian Nat Prod Res; 2024 Apr; ():1-38. PubMed ID: 38647682
[TBL] [Abstract][Full Text] [Related]
7. A novel Imidazo[1,2-a]pyridine derivative modulates active KRAS
Ali Y; Khan AA; Alanazi AM; Fatima S; Kozmon S
Int J Biol Macromol; 2024 Jun; 270(Pt 2):132477. PubMed ID: 38772459
[TBL] [Abstract][Full Text] [Related]
8. Glimmers of hope for targeting oncogenic KRAS-G12D.
Tang D; Kang R
Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
[TBL] [Abstract][Full Text] [Related]
9. Inhibition mechanism of MRTX1133 on KRAS
Liang F; Kang Z; Sun X; Chen J; Duan X; He H; Cheng J
J Comput Aided Mol Des; 2023 Mar; 37(3):157-166. PubMed ID: 36849761
[TBL] [Abstract][Full Text] [Related]
10. KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Bannoura SF; Khan HY; Azmi AS
Front Oncol; 2022; 12():1013902. PubMed ID: 36531078
[TBL] [Abstract][Full Text] [Related]
11. Anti-dengue infectivity evaluation of bioflavonoid from
Dwivedi VD; Bharadwaj S; Afroz S; Khan N; Ansari MA; Yadava U; Tripathi RC; Tripathi IP; Mishra SK; Kang SG
J Biomol Struct Dyn; 2021 Mar; 39(4):1417-1430. PubMed ID: 32107969
[TBL] [Abstract][Full Text] [Related]
12. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of purine and pyrimidine-based
Park SY; Gowda Saralamma VV; Nale SD; Kim CJ; Jo YS; Baig MH; Cho J
Heliyon; 2024 Apr; 10(7):e28495. PubMed ID: 38617914
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
15. KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge.
Mao Z; Xiao H; Shen P; Yang Y; Xue J; Yang Y; Shang Y; Zhang L; Li X; Zhang Y; Du Y; Chen CC; Guo RT; Zhang Y
Cell Discov; 2022 Jan; 8(1):5. PubMed ID: 35075146
[TBL] [Abstract][Full Text] [Related]
16. Identification of potential inhibitor targeting KRAS mutation in Papillary Thyroid Carcinoma through molecular docking and dynamic simulation analysis.
Tayubi IA; Madar IH
Comput Biol Med; 2023 Jan; 152():106377. PubMed ID: 36493736
[TBL] [Abstract][Full Text] [Related]
17. Discovering and Targeting Dynamic Drugging Pockets of Oncogenic Proteins: The Role of Magnesium in Conformational Changes of the G12D Mutated Kirsten Rat Sarcoma-Guanosine Diphosphate Complex.
Hu Z; Marti J
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430338
[TBL] [Abstract][Full Text] [Related]
18. New lead compounds identification against KRas mediated cancers through pharmacophore-based virtual screening and in vitro assays.
Ghufran M; Rehman AU; Ayaz M; Ul-Haq Z; Uddin R; Azam SS; Wadood A
J Biomol Struct Dyn; 2023; 41(16):8053-8067. PubMed ID: 36184737
[TBL] [Abstract][Full Text] [Related]
19. Crystal Packing Reveals a Potential Autoinhibited KRAS Dimer Interface and a Strategy for Small-Molecule Inhibition of RAS Signaling.
Brenner RJ; Landgraf AD; Bum-Erdene K; Gonzalez-Gutierrez G; Meroueh SO
Biochemistry; 2023 Nov; 62(22):3206-3213. PubMed ID: 37938120
[TBL] [Abstract][Full Text] [Related]
20. Computational investigation to identify potent inhibitors of the GTPase-Kirsten RAt sarcoma virus (K-Ras) mutants G12C and G12D.
Kumar SU; Priya Doss CG
Comput Biol Med; 2021 Dec; 139():104946. PubMed ID: 34715554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
